Superinfection of different viral strains within a single host provides an opportunity for studying host-virus and virus-virus interactions, including viral interference and genetic recombination, which cannot be studied in infections with single viral strains. Hepatitis C virus (HCV) is a positive single-strand RNA virus that establishes persistent infection in as many as 85% of infected individuals. However, there are few reports regarding coinfection or superinfection of HCV. Because of the lack of tissue culture systems and small animal models supporting efficient HCV replication, we explored these issues in the setting of liver transplantation where both recipient and donor were infected with different HCV strains and therefore represent a distinct model for HCV superinfection. Serial serum samples collected at multiple time points were obtained from 6 HCV-positive liver donor/recipient pairs from the National Institute of Diabetes and Digestive and Kidney Diseases liver transplantation database. At each time point, HCV genotype was determined by both restriction fragment length polymorphism analysis and phylogenetic analysis. Furthermore, we selectively sequenced 3 full-length HCV isolates at the earliest time points after liver transplantation, including both 5 and 3 ends. Detailed genetic analyses showed that only one strain of HCV could be identified at each time point in all 6 cases. Recipient HCV strains took over in 3 cases, whereas donor HCV strains dominated after liver transplantation in the remaining 3 cases. In conclusion, in all 6 cases studied, there was no genetic recombination detected among HCV quasispecies or between donor and recipient HCV strains. (HEPATOLOGY 2003;38:
H epatitis C virus (HCV), a single-strand, positive RNA virus, has been well documented as the major etiologic agent responsible for most posttransfusional and community-acquired hepatitis. 1 HCVrelated liver disease is now a leading cause for liver transplantation in the United States. One striking characteristic of HCV infection is its high chronicity rate; that is, it easily establishes persistent infection in up to 85% of infected individuals and causes a wide spectrum of clinical profiles. The high chronicity rate of HCV may be partially attributed to its great genetic variability, which favors its rapid adaptation to a given biological environment. HCV may be divided into at least 6 major genotypes and more than 30 subtypes according to the phylogenies of available HCV sequences. 2 Moreover, even in patients infected with a single HCV subtype, HCV circulates as a group of variants with up to 10% nucleotide sequence difference, termed quasispecies. [3] [4] [5] [6] [7] Superinfection with different viral strains within a single host is a useful model for studying host-virus and virus-virus interactions. In HCV, perhaps due to the lack of protective immunity, 8 superinfection by different HCV isolates in patients with chronic HCV is clinically observed, in particular in individuals at very high risk for infection, such as injection drug users and patients on hemodialysis. [9] [10] [11] There is also serologic evidence that patients with HCV infected with a single genotype may experience transient or occult superinfection with differ-ent genotypes of HCV. 12 HCV superinfection often results in elevated transaminase levels. However, the mechanisms underlying the interaction among different HCV strains during the superinfection are unclear with regard to either the establishment of a coinfection status or the takeover by one of the HCV strains. In the present study, we explore these issues in the setting of liver transplantation in which both the recipient and the donor are infected with HCV, a model of HCV superinfection. Using molecular cloning and genetic analysis, we examined genetic outcomes of either donor or recipient HCV strains after liver transplantation. We also studied several biological events related to viral superinfection, such as genetic recombination and viral interference.
Patients and Methods
Patients. Six cases had been previously identified in which both the recipient and the donor were HCV RNA positive in a prospective study to evaluate recurrent HCV infection after liver transplantation. 13 Serum samples from the recipients were collected at multiple time points before and after liver transplantation. Serum samples from the donors were collected at the time of transplantation.
HCV RNA Detection, Genotyping, and Quantitation. At each time point, HCV infection was confirmed by reverse-transcription polymerase chain reaction (PCR) of the 5Ј end of the HCV genome. The PCR products were further used to determine HCV genotypes by restriction fragment length polymorphism analysis as previously described. 14 We also determined HCV genotype by phylogenetic analysis of HCV envelope sequences (see following text). The level of HCV RNA was quantitated by branched DNA assay. 14 Molecular Cloning of HCV E1/E2 Domain. A 1.37-kilobase of fragment covering HCV E1/E2 domain was amplified by reverse-transcription PCR as previously described. 15 The contamination-prevention measures suggested by Kwok and Higuchi were adopted in all assays. 16 PCR product was purified with QIAquick PCR Purification Kit (Qiagen, Chatsworth, CA) and digested with EcoRI and BglII. After gel purification with QIAquick Gel Extraction Kit (Qiagen), the digested PCR product was ligated into pUC19 predigested with EcoRI/ BamHI. A total of 3.0 L of ligation product was then transformed into 50 L of competent Escherichia coli cells (JM109) prepared by the modified rubidium chloride protocol and was plated on Luria-Bertani agar plates containing 50 g/mL ampicillin. Approximately 8 independent clones were randomly picked for miniculture in 2 mL of Luria-Bertani medium containing 50 g/mL ampicillin. Recombinant plasmids were purified with plasmid DNA Purification Kit (Qiagen), and PCR insert was confirmed by repeating 17 cycles of second-round PCR. A total of 4.5 L purified recombinant plasmid was used as the template for automated sequencing with ABI PRISM dye terminator cycle sequencing ready reaction kit on the ABI 373A automated sequencer (Applied Biosystems, Foster City, CA). Both strands of recombinant plasmids were sequenced using primers from the vector and gene-walking primers from the HCV sequence.
Full-Length Sequencing of HCV Isolates. We sequenced 3 full-length HCV isolates (all genotype 1a) from selected samples (Table 1) . A PCR strategy was adopted for this aim. 17, 18 Thus, the whole HCV genome was divided into 10 fragments named fragments b through k (Fig. 1) , and each fragment was amplified by reverse-transcription PCR with genotype 1a-specified primers ( Table 2 ). The PCR protocol was the same as that described for the amplification of HCV E1/E2 domain. PCR products were gel purified as previously described and directly served as the templates for sequencing. Because there is an overlapping sequence domain between 2 To determine sequences of both the 5Ј and 3Ј ends of the HCV (fragment a and l) (Fig. 1) , we adopted a modified protocol of the rapid amplification of complementary DNA (cDNA) ends. Briefly, 5 L of extracted RNA was used for reverse transcription with primer HCVR3, 5Ј-AAC TCC ACC AAC GAT CTG AC-3Ј, nucleotide no. 424 to 443. Three reverse-transcription reactions were combined (60 L) and incubated with 6 L of 6N NaOH for 30 minutes at 37°C, followed by the addition of 6 L of 6N acetic acid. cDNA was purified using QIAquick Nucleotide Removal Kit (Qiagen) and eluted by 20 L of Tris buffer. A 5Ј-phosphorylated 42-base pair oligonucleotide A1 for RNA ligation was synthesized and purified from 12% acrylamide/8 mol/L urea gel (Invitrogen, Carlsbad, CA): A1, 5Ј-PGTC TCG AAT TCG GTA CCA GGT AGC TAG CAA CTA GAC TAG TGC -3Ј. To prevent intramolecular and intermolecular ligation of oligonucleotides, 3Ј terminus of A1 was blocked by mixing 0.5 nmol of A1, 20 nmol of dideoxyadenosine triphosphate (Invitrogen), 1 mmol/L CoCl 2 , and 50 U terminal transferase (Roche Applied Science, Branchburg, NJ) in a total of 20 L reaction volume. To incorporate A1 into the 3Ј end of HCV cDNA, ligation was prepared by mixing 12 L purified HCV cDNA, 1 L 3Ј end blocked A1, 16 L 50% polyethylene glycol, 1 L RNasin (Promega, Madison, WI), 10 U T4 RNA ligase (Promega), and buffer in a total of 40 L of reaction volume. The reaction was incubated at 16°C overnight. HCV cDNA-A1 was purified using QIA II Gel Extraction Kit (Qiagen) and eluted into 20 L of Tris buffer.
Next, 5 L of HCV cDNA-A1 was used as the template for seminested PCR. The protocol was similar to that previously described except primers were changed. Primers for the first round were as follows: A2, 5Ј-AGT CTA GTT GCT AGC TAC CTG G-3Ј; HCVXR2, 5Ј-ACT CGA GAT CTC CCT ATC AGG CAG TAC CAC AA-3Ј (nucleotide no. 281-300). For the second round, primers HCVXR2 and A3, 5Ј-GTA CTA GCT AAC CTG GTA CCG AAT TCG-3Ј, were applied. The resulting PCR product was cloned into pUC19, followed by the transformation into JM109 cells. Approximately 5 independent clones were sequenced as previously described.
To determine the sequence of the HCV 3Ј end, RNA was directly ligated with blocked A1 in the presence of 10% dimethyl sulfoxide in a total reaction volume of 20 L. A total of 2 L of reaction was directly used as template of reverse-transcription PCR with primers 3F1 and A2 for the first round and 3F2 and A3 for the second round. A3 was also used as the primer for reverse transcription: 3F1, 5Ј-TTC AAC TGG GCA GTA AGA AC-3Ј (9177-9176); 3F2, 5Ј-ACT CGA GAT CTA ACA AAG CTC AAA CTC ACT CC-3Ј (9194-9214). The protocols for cloning and sequencing were the same as that previously described. The nucleotide numbering of primer sequences is according to HCV J1 strain (GenBank accession no. D10750).
Genetic Analysis. The sequences were edited and aligned with SeqEd program in the Wisconsin GCG package (Oxford Molecular Group, Inc., version 10.0) and Clustal W (version 1.74). 19 Sequences of primers were removed before genetic analysis. All phylogenetic trees in this study were constructed using 2 methods: (1) neighbor-joining tree 20 with a bootstrap test, implemented in the Molecular Evolutionary Genetics Analysis (MEGA) program, 21 and (2) maximum likelihood tree, implemented in the PHYLIP package. 22 Nucleotide distance matrices were produced with the Kimura 2-parameter formula. 23 Sequence variability was evaluated at the amino acid level by calculating the rate of amino acid substitution. The amino acid sequences were aligned; a consensus of either donor or recipient sequences, whichever became dominant, collected at the earliest time point (time 0), was made for each patient. The average number of amino acid changes from the consensus was then plotted for each time point.
Detection of Recombination. To detect possible recombination signals among sequences, we combined several different approaches including phylogenetic profiles, SplitTree analysis, and SimPlot analysis. In phylogenetic profiles, the serial neighbor-joining trees, constructed using 250 base pairs as basic length, were moved from the 5Ј end to the 3Ј end of the sequences with a 60 -base pair increase. If recombination did occur, the HCV isolates containing mosaic sequences might change their positions in tree topology, providing an initial clue to possible recombination. In the SplitTree program, phylogenetic trees were constructed using the method of split decomposition, which takes into account that real evolutionary data contain a number of different and sometimes conflicting signals that therefore results in the appearance of tree-like networks but not bifurcating trees. 24 It may give a preliminary search of recombination in given sequences. Finally, the similarity scores between the sequences tested and reference sequences were calculated in a sliding window using the SimPlot program, 25 which may also give an indication of recombination if it does occur.
To search for possible phylogenetic evidence of HCV recombination, we further retrieved 54 full-length HCV sequences from the GenBank database. To reduce the redundancy of sequences, only one HCV isolate was selected from a group of sequences produced from an individual. Each full-length HCV sequence was aligned with the HCV J1 strain (GenBank accession no. D10750) presumed as a "standard" sequence template. In-frame insertions were removed, and gaps were ignored in the phylogenetic analysis. The final version of the 54 edited full-length sequences contained a partial sequence of the 5Ј end and the entire coding domain. Extreme sequences of the 3Ј end of HCV were not included. The 54 fulllength HCV sequences have been designated as HCV1 through HCV54, respectively, and given GenBank accession numbers M62321, M67463, D10749, M58335, D90208, D01171, X61596, D10934, S62220, L02836, M96362, U01214, D50483, M84754, D30613, U45476, D10750, D14853, AB031663, D00944, AF169003, AF177040, D01221, D50409, D17763, D28917, AF046866, D26556, Y11604, AF064490, Y13184, Y12083, D63821, D63822, AF165060, AJ000009, AJ132997, D84265, AF278830, AB016785, AB030907, AB047640, AB049101, AF064490, AF139594, AF176573, AF207768, AF238385, AJ238800, D13558, D14484, D89815, D84262, and AF238486, respectively.
Statistical Analysis. Statistical analysis, including multiple-sample t test, multiple-variable line analysis, Fisher's exact test, and 2 tests, was performed with SPSS software (version 6.0; SPSS Inc., Chicago, IL).
Nucleotide Sequence Accession Numbers. The sequences produced in this project are available in GenBank with accession numbers AF511727 through AF511950. Among them, AF511948, AF511949, and AF511950 represent 3 full-length HCV sequences.
Results
Predominance of HCV Infection After Liver Transplantation. At each time point, only one HCV genotype was identified by restriction fragment length polymorphism analysis in all 6 cases (Table 1) . We further sequenced 221 clones representing HCV envelope sequences (each 1,020 base pairs in length) collected at a total of 28 time points from all patients. Phylogenetic analysis of these clones confirmed the genotyping results of restriction fragment length polymorphism analysis (Fig. 2) . The predominance of HCV strains, either from recipients in cases 1, 4, and 5 or donors in cases 2, 3, and 6, was established as early as 4 months after transplantation and remained so up to the last time point studied (Fig. 2) . The simultaneous existence of both donor and recipient HCV strains at any postoperation time point could not be identified.
Sequence Variability Assessed by Amino Acid Substitutions. To evaluate the changes over time of sequence variability, we calculated the average number of amino acid changes from the consensus sequence at time 0 of the sequences that became dominant for each time point in each case. The lower variability of donor-dominant sequences at time point 0 was found (Fig. 3A) . There were fewer than 3 amino acid differences on average within the donor-dominant sequences; there were no less than 3 within the recipient-dominant sequences (Fig. 3B) . For donor-dominant sequences, a decrease or a constant number of amino acid changes persisted from 6 to 12 months, after which sequence diversity increased dramatically. By 20 months, both recipient-and donor-dominant sequences changed at a more constant rate of about 3 amino acids per year.
Genetic Characteristics of 3 Full-Length HCV Isolates. In cases 1, 3, and 6, we selectively sequenced fulllength HCV cDNA at the earliest time point (4 months after liver transplantation). HCV genotype 1a dominated after surgery in these 3 cases, and both donors and recipients were infected with different HCV genotypes: 1a and 2b in case 1 and 1a and 1b in cases 3 and 6 (Table 1) . Thus, if recombination between donor and recipient HCV strains had occurred, the full-length HCV se- Fig. 2 . Neighbor-joining trees constructed by PHYLIP (version 3.573), with nucleotide distance matrices computed using the Kimura 2-parameter formula and using the data from all clones (each 1,020 base pairs) derived at all time points for each case. Bootstrap tests were performed with 100 replicates, and values are shown at major branches. The trees clearly show that only one HCV strain either from the donors (cases 2, 3, and 6) or the recipients (cases 1, 4, and 5) dominated after liver transplantation. The labeling of clones in each case was according to sample numbers (see Table 1 ).
quences at 4 months should contain genetic information from both genotypes, which should have been detected by our approaches. We were able to amplify all PCR fragments with HCV genotype 1a-specific primers (Fig. 1) . We also determined the sequences from the HCV 5Ј and 3Ј ends except the extreme sequence of the HCV 3Ј end. Three full-length HCV sequences were then assembled to 9,424, 9,426, and 9,359 base pairs for cases 1, 3, and 6, respectively. They had high sequence homology compared with HCV J1 strain (GenBank accession no. D10749, HCV genotype 1a) as 94%, 93%, and 94% nucleotide similarity, respectively. Sequence alignments with documented HCV genotype 1a sequences in GenBank did not show insertions or deletions. No recombination was found in these 3 full-length HCV sequences (see following text).
Lack of HCV Recombination in All Sequences Tested. Applying 3 different approaches, phylogenetic profiles, SplitTree analysis, and SimPlot analysis, we were unable to find evidence for possible HCV genetic recombination in the 3 types of sequence data we obtained, namely, 221 HCV envelope sequences (each 1,020 base pairs) in all 6 transplantation cases, 3 full-length HCV sequences in cases 1, 3, and 6, and 54 full-length HCV sequences retrieved from GenBank. We could not show a change in branch positions in tree topology in the analysis of phylogenetic profiles (see previous text for a detailed description). Bifurcating trees in SplitTree analysis were consistently formed with different HCV domains, indicating the lack of conflicting signals among the sequences analyzed (Fig. 4) . In SimPlot analysis, there was no conflicting signal detected along with the entire HCV sequence analyzed (Fig. 5) . Therefore, genetic recombination was not detected among HCV quasispecies variants at each time point. There was no recombination between donor HCV strains and recipient HCV strains. There was no phylogenetic evidence for HCV recombination among full-length HCV sequences.
Discussion
In this study, we examined genetic dynamics of HCV in the setting of liver transplantation in which both donors and recipients were infected with different HCV strains. There were several important findings. First, only one HCV strain, either from the recipient or the donor, was predominant after liver transplantation as assessed by both restriction fragment length polymorphism analysis and phylogenetic analysis. We could not detect the simultaneous existence of 2 different HCV strains at any time point even in cases 2 and 5, in which HCV strains from the donor and the recipient belonged to the same HCV subtype (1a) (Fig. 1) . Although we sequenced approximately 8 clones at each time point, the possibility of simultaneous existence of 2 HCV strains at a given time point cannot be completely excluded. It is possible that minor HCV strains may be present at a level beyond the limits of detection used in this report and therefore may become dominant again during the patient's life due to changes in the environment where the virus replicates.
We could document only a single HCV strain at the earliest sampling time point (4 months after liver transplantation). In a similar study, Laskus et al. found that replacement by donor HCV strains could occur at their earliest sampling point (1 month after surgery). 26 Taken together, these findings indicate that superinfection with different HCV strains may be a temporary process and a coinfection status is hardly ever established. 27 Previous reports of a high rate of coinfection may be overestimated, [28] [29] [30] perhaps attributed to the methods used for HCV genotyping (see following text). We also failed to find any relationship between dominance of a particular viral strain and baseline parameters such as age, sex, viral load, and alanine aminotransferase level (Table 1 ). There was no obvious relationship between dominance and genetic diversity assessed by the branch-length method at each time point 31 (data not shown). Thus, in cases 1, 4, and 5, where the recipient HCV strain dominated, the genetic diversity of recipient HCV strains was higher than that of donor HCV strains. However, this was not the case in the group in which the donor HCV strains dominated. If the final outcome of virus competition is mainly determined by inherent fitness, we could find an overall trend, namely, 1a dominates over 1b, which dominates over 2a. This is similar to the finding by Vargas et al. that HCV genotype 1b is dominant after liver transplantation in which both donors and recipients were HCV RNA positive. 32 Although the dominance we observed could be explained by the competitive exclusion principle of classic population theory, which predicts the final overgrowth of one virus during the course of mixed infection, it is unclear at the molecular level how this "replacement" event occurs within the liver. The HCV RNA levels are quite different in different anatomic sites within the liver. 33 Also, it has been found that HCV only infects about 5% to 25% of hepatocytes. 34 These observations point out the possible existence of "replicative space" within the liver for HCV, 35 as has been suggested for hepatitis B virus. 36 When recipient HCV strains replaced the donor's, as seen in cases 1, 4, and 5, it is not clear if the recipient HCV strains infected the same population of hepatocytes holding donor HCV or infected new hepatocytes. In the former situation, the "replacement" may be the result of competition between recipient and donor HCV strains for host cellular factors necessary for viral replication. If the latter is true, the exclusion or significant suppression of donor HCV strains may be the outcome of the immune response generated during the period of chronicity preceding transplantation. Further elucidation of these issues A full-length HCV isolate (genotype 1a, AF511948), derived 4 months after transplantation in case 1, was compared with 2 other full-length HCV isolates (genotype 1a) sequenced in this study (AF511949 and AF511950) and reference HCV sequences of subtypes 1a (M62321, AF009606), 1b (AF356827, AB049101), and 2b (AF238486, AB030907). At the top of the chart, the HCV isolate AF511948 clearly groups together with HCV isolates AF511949 and AF511950 (black lines) and genotype 1a reference sequences (dark gray lines). In the middle and bottom of the chart, HCV genotype 1b and 2b reference sequences group together, respectively. There is no sign of recombination in any of the sequences.
requires close observation of both liver histology and viral dynamics immediately after liver transplantation.
Viral interference has been suggested in patients with chronic HCV who are coinfected or superinfected with other hepatotropic viruses, such as hepatitis B virus. 37 In this study, we have indirect evidence supporting the idea that some types of interaction may occur between recipient and donor HCV strains. Thus, we found that the average rate of amino acid change after liver transplantation, with either donor or recipient HCV strains dominating, was 3 amino acids per year. In our recent work studying posttransplant amino acid changes in HCV-positive patients who received livers from HCV-negative donors, we found that the rate of posttransplant amino acid change for this group of patients was about one amino acid per year. 38 Therefore, the rate of amino acid change increases 3-fold when both recipient and donor are HCV positive over the time period of this study.
Significantly, we failed to find evidence for recombination among viral quasispecies or between donor and recipient HCV strains, even by the full-length HCV sequencing. There is no phylogenetic evidence of recombination by analyzing 54 full-length HCV isolates retrieved from the GenBank database. Recombination is a common phenomenon for viruses with an RNA genome, such as human immunodeficiency virus 39, 40 and influenza virus. 41 There is also phylogenetic evidence of recombination for dengue virus 42 and hepatitis G virus, 43 both of which belong to the Flaviviridae as the HCV. Although recombination, together with mutation and reassortment (for segmented RNA virus), are 3 major molecular events contributing to the genetic diversity of RNA viruses, only mutations and deletions have been observed in almost all HCV diversity studies. Kalinina et al. recently reposted an HCV recombinant, HCV RF1_2k/1b. 44 However, it would be important to follow such possible recombination because samples may have been collected at the time of temporary superinfection (see previous text) during which the preference of PCR amplification on different HCV domains of different HCV genotypes may result in misleading information, which may also partially explain the discrepancy of HCV genotyping based on different regions of HCV. 45 Because of a rapid process of HCV superinfection, it may be difficult to detect in clinical situations. Therefore, the frequency of HCV superinfection may be underestimated. During HCV superinfection, it is possible that a single hepatocyte may be infected by 2 different HCV strains, a basic prerequisite for the production of viral recombinants (recombination may also occur between members of a quasispecies or between host and virus with less frequency). Thus, it is unclear why there are few reports of HCV recombinants. One possibility is that recombination does occur during superinfection. However, recombinants are not selected or constitute only minor viral populations due to their reduced fitness. 46 Another possibility is the existence of the socalled superinfection exclusion phenomenon in which HCV-infected hepatocytes show diminished capability to be infected again by the virus. 47, 48 These issues could be experimentally addressed with cell culture inoculated with 2 different HCV strains in the future.
Finally, our data showed that it is possible for HCV genotype 1a to have the greatest potential for rapidly spreading due to its capability to take over other genotypes when superinfection occurs. This is consistent with the finding by Pybus et al. using a mathematical model that predicts the predominance of HCV genotype 1a in the future. 49 Besides its epidemiologic importance, this finding also has implications for the design of a vaccine to control HCV infection, with genotype 1a perhaps being a better candidate than other genotypes if it tends to dominate.
In summary, we studied HCV superinfection in the setting of liver transplantation where both the donor and the recipient were infected with different HCV strains. We found that superinfection is a rapid process and only one HCV strain, either from the donor or the recipient, finally dominated and persisted up to 4 years after surgery. During this process, there is no genetic recombinant detected among HCV quasispecies and between donor and recipient HCV strains. Understanding the molecular events underlying our observations warrants further investigation in cell culture or small animal model systems when these are available.
